We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA hit Enzyvant with a complete response letter for its regenerative tissue therapy RVT-802, an investigational drug for a rare immunodeficiency disorder. Read More
Novartis’ blockbuster multiple sclerosis drug Gilenya (fingolimod) may soon face generic competitors in the U.S., following three FDA approvals. Read More
The FDA continued to lead the world in new molecular entity approvals in fiscal year 2019, according to a senior official in the Office of New Drugs. Read More
Lexicon Pharmaceuticals has lost its appeal to the FDA of the agency’s complete response letter in March for its investigational add-on type 1 diabetes treatment Zynquista (sotagliflozin). Read More
In a move to help sponsors of insulin biosimilar applications, the FDA spelled out the data and information needed to support immunogenicity assessments for insulin biosimilars or interchangeables in a draft guidance released on Monday.
Read More
The FDA handed out its 25th biosimilar approval to Pfizer’s Humira biosimilar Abrilada (adalimumab-afzb) for treating multiple inflammatory conditions. Read More
Lipocine has received a third complete response letter from the FDA for its novel oral testosterone replacement therapy Tlando for treatment of male hypogonadism. Read More
The FDA has revoked Indivior’s orphan drug designation for its opioid addiction treatment Sublocade (buprenorphine extended-release injection) finding that it was improperly granted. Read More
Recro Pharma announced that the FDA granted its appeal of a complete response letter to an NDA for its intravenous pain medication meloxicam. Read More
Aquestive submitted a citizen petition to the FDA urging the agency to delay approval of Neurelis’ new drug application for its cluster seizure nasal spray Valtoco (diazepam intranasal solution) pending additional clinical studies. Read More
The FDA on Tuesday approved Sandoz’s Ziextenzo (pegfilgrastim-bmez), marking the agency’s 24th biosimilar approval and the third biosimilar of Amgen’s Neulasta. Read More